If you're from Japan, you're probably wondering why I've listed PSK under alternative therapies. In Japan, PSK is an approved anti-cancer drug with 20 years of research behind it. PSK sales in Japan account for hundreds of millions dollars worth of sales each year. But in the US, PSK is little known, is not used by mainstream doctors, and until recently nothing like it was readily available. Now a nutritional supplement designed to be identical to PSK is available in the US, but very few mainstream doctors, and actually not many alternative practitioners are aware of it. So in the US, PSK has the status of a little known nutritional supplement or alternative therapy. Which is too bad in light of its proven benefits, easy administration, and lack of toxicity. Before I start sounding too much more like an advertisement, let me confess. I really am excited about it, but I have no financial interest in it; I'm not selling it.
This weekend I saw the movie "50/50," the story of a young cancer patient who faced even odds of surviving his disease. I wasn't sure I wanted to see a cancer movie - after all, I see cancer often enough in real life on the oncology ward where I work.
Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study -- Brewer et al. 6 (1): 1 -- Clinical Cancer Research
CancerGuide is a cancer information page written by Steve Dunn, a fellow patient.
I strongly believe, and indeed I know from personal experience, that information can save your life. This page is dedicated to helping cancer patients find the best treatment for their disease by finding, and understanding, the best and latest information on their disease. The focus here is on technical information.
While this page does offer links to the best cancer information sources on the net, what makes this page special is no holds barred help and information about things on and off the net from someone who's been been where you are now. The information on this page is information with a point of view, not information sanitized by committee!
...has been the number one Google search term leading people to the blog this week - and that worries me.
As I wrote about a week ago, dichloroacetate, or DCA, is the molecule tested recently by a team at University of Alberta for its ability to slow the growth of human lung cancer in immunocompromised rats. Among DCA's action is the ability to prevent cancer cells from producing lactic acid via aerobic glycolysis, a process used by more than half (but not all) tumors. Scientists continue to debate whether this process is a cause of cancer, or just a byproduct of malignant cell transformation.
I am deeply concerned that desperate cancer patients may be trying to purchase dichloroacetate (DCA) and self-treat for cancer based on this highly-hyped single paper. To the credit of the researchers and their institution, who have set up a website to address the intense interest, they discourage such practice:
Targeted cancer therapy and gene therapy have been mentioned in the blue before, but oncolytic viruses are the hot young thing. For consideration in cancer treatment, an virus must replicate in and kill a high number of exclusively cancer cells, while sparing healthy tissue. A Philadelphia-based company called Neotropix has won awards for its research into a prime contender - the Seneca Valley Virus. It has been the subject of Phase I adult clinical trials, with Phase II adult and Phase I pediatric clinical trials to start this year. SVV has advantages over some other contenders in that it is a naturally occurring (lest we create a race of mutant zombies) organism and studies so far suggest it is not harmful to healthy human cells. While a number of other oncolytic viruses are being examined, NTX-010 seems able to treat a very wide range of common and rare forms of cancer, some of which are now considered uniformly fatal. In addition, unlike some other tested viruses, it can travel through the bloodstream to treat metastatic and not just local disease. Compared to the side-effects and late effects of chemotherapy and radiation treatment, and because many of the cancers ideal for treatment with an oncolytic virus have no surgical options, this may be the next big breakthrough.
A multicountry ecologic study of risk and risk reduction factors for prostate cancer mortality.
Grant WB.
Eur Urol. 2004 Mar;45(3):271-9.
PMID: 15036670
CONCLUSIONS: These results are consistent with insulin-like growth factor-I (IGF-I), being an important risk factor for prostate cancer, with alcohol and calcium being less important risk factors, and with allium family vegetables, and, to a lesser extent, vitamin D being important risk reduction factors. These results should provide guidance for additional studies on dietary and environmental links to prostate cancer.
The Author
The author of this site is the British writer, John Davidson.
Please note that the author is neither a doctor, nor a qualified health practitioner. Every cancer patient should always consult his or her medical practitioner with regard to the use of complementary remedies or treatments, and nothing on this site should be construed in any way as medical or therapeutic advice. It is simply the result of one person's search for solutions. Please read our disclaimer.
About This Site
Internet searches trawl up vast amounts of information about cancer, from a broad spectrum of viewpoints. The information and internet links on this site are for those seeking to augment the treatment offered by their hospital oncology (cancer) unit. Of course, a great many other internet sites concerning cancer can be found by keying the requisite search words into any of the major search engines.
The content of this site was initially prepared, at the request of medical and nursing staff and others, some weeks after I had had an emergency operation for the removal of a colon cancer, and while undergoing chemotherapy in case any cancer cells had gone AWOL. There had been some escape of cancer cells into associated lymph nodes (3 out of 17, including the most distal), but no other tumours had been picked up by a CT scan.
When I returned home from hospital in September 2005, with the help of friends, I started doing some research on cancer. I was amazed to discover that despite the billions of pounds/euros/dollars etc. spent on cancer research, and the many advances in understanding the numerous variants of the disease, the standard treatment for my stage of colon cancer is still a drug (fluorouracil, also called 5FU) that has been in use for more than forty years, has uncomfortable side effects, and which only increases the chances of survival after five years by 5 to 10%.